Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2025

Nov 19, 2025

30604_dirs_2025-11-19_2664f85d-d736-4b0d-aafb-93f08fd82b8d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-11-17

Reporting Person: Lo Andrew (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-17 Common Stock S 36801 $66.6263 Disposed 17887 Direct
2025-11-17 Common Stock S 3798 $67.056 Disposed 14089 Direct
2025-11-18 Common Stock S 24007 $65.2315 Disposed 81576 Indirect
2025-11-18 Common Stock S 30993 $66.049 Disposed 50583 Indirect

Footnotes

F1: Represents the weighted average sale price of the shares sold from $65.975 to $66.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F2: Represents the weighted average sale price of the shares sold from $66.975 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: Represents the weighted average sale price of the shares sold from $64.58 to $65.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F4: Represents the weighted average sale price of the shares sold from $65.58 to $66.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.